[微生物实验室的分析前质量评估]

[Pre-analytical quality assessment in the microbiology laboratory].

作者信息

Carbajal-Vázquez Meztli Monserrat, Carrillo-Montes María Guadalupe, Rivera-Leaños Roxana Blanca, Farias-Basurto Verónica Alicia, Bárcena-Molina César

机构信息

Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Cardiología, Laboratorio. Ciudad de México, México.

Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Unidad de Educación e Investigación, Coordinación de Investigación en Salud, División de Desarrollo de la Investigación en Salud. Ciudad de México, México.

出版信息

Rev Med Inst Mex Seguro Soc. 2024 Feb 5;62(suppl 1):1-7. doi: 10.5281/zenodo.10790465.

DOI:10.5281/zenodo.10790465

PMID:39586768

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12564796/

Abstract

BACKGROUND

Errors in the pre-analytical phase of the microbiology laboratory reduce patient safety and generate additional expenses. In Mexico we do not have systems for evaluation and monitoring of the pre-analytical phase; quality indicators are proposed for continuous improvement.

OBJECTIVE

Identify the main reasons for rejection of respiratory samples in the microbiology laboratory and evaluate the usefulness of preanalytical quality indicators.

MATERIAL AND METHODS

Cross-sectional study. Review of microbiology laboratory applications from August 2022 to July 2023, calculated the frequency of rejection and identification of the main reasons for it, it was analyzed using quality indicators based on the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

RESULTS

Of 3530 processing requests, 582 were for respiratory samples (16.48%), 44 samples rejected due to pre-analytical errors (7.56%), the main causes identified: Transcription error 22.7%, identification error 20.4%, Samples that do not comply Murray-Washington criteria 25.0%, Errors in obtaining/collecting samples 20.4%, Samples with defects in conservation 4.5%, Unidentified samples: 6.8.

CONCLUSIONS

The main causes of rejection were identified; upon analysis with the preanalytical quality indicators, they were found at desirable levels and in reference ranges; only 4 were useful for long-term implementation.

摘要

背景

微生物实验室分析前阶段的错误会降低患者安全性并产生额外费用。在墨西哥，我们没有用于评估和监测分析前阶段的系统；提出了质量指标以持续改进。

目的

确定微生物实验室呼吸道样本拒收的主要原因，并评估分析前质量指标的有用性。

材料与方法

横断面研究。回顾2022年8月至2023年7月微生物实验室的申请，计算拒收频率并确定主要原因，使用基于国际临床化学和检验医学联合会（IFCC）的质量指标进行分析。

结果

在3530份检测申请中，582份是呼吸道样本（16.48%），44份样本因分析前错误被拒收（7.56%），确定的主要原因：转录错误22.7%，识别错误20.4%，不符合Murray-Washington标准的样本25.0%，获取/采集样本错误20.4%，保存有缺陷的样本4.5%，未识别样本：6.8。